CoQ10: A Few Real Niches, Not the Anti-Aging Energy Booster

Summary

CoQ10 is sold as a "cellular energy and anti-aging" tonic for everyone, and that pitch is unsupported — healthy people make enough of their own, there is no energy or longevity benefit in people who are not deficient, oral absorption is only a few percent without dietary fat, and even its flagship consumer use (statin muscle pain) has genuinely conflicting trials — yet the supplement is not a nothing: it has a handful of real, narrow niches where the evidence holds up (a mortality signal in chronic heart failure from the Q-SYMBIO trial, obligatory replacement in primary CoQ10 deficiency and mi

Why Moderate

Moderate Evidence because the entry's verdict blends parts of very different strength. The mass-market debunk (no benefit in healthy adults) and the absorption reality (poorly absorbed, take with fat) are high-confidence, but the niches that make CoQ10 worth discussing at all sit at Moderate or below: the heart-failure signal rests on one manufacturer-funded, unreplicated RCT; the statin-myopathy use has genuinely conflicting trials; the migraine benefit is a small RCT plus a supportive meta-analysis confined to frequency and duration; and the mitochondrial-disease use is standard-of-care by mechanism rather than by large trials. The overall entry inherits the confidence of its load-bearing therapeutic claims, which is Moderate.

NOT Foundational because there is no single undisputed axiom here — the entry carries clinical and commercial judgement and a live both-ways tension (real niches versus unsupported mass-market pitch).

NOT Strong because the therapeutic anchors are not gold-standard: the heart-failure claim is one unreplicated sponsor-funded trial, and the flagship consumer use is unresolved. Only the debunk and the pharmacokinetics reach high confidence, and the entry marks those explicitly rather than letting them lift the whole verdict.

The per-use split (read this, not just the headline):
• No energy/anti-aging benefit in healthy adults: Strong (independent, converging).
• Absorption ~2–3%, take with fat, formulation over form: Strong (well-established pharmacokinetics).
• Heart-failure mortality signal: Moderate (one unreplicated, manufacturer-funded RCT).
• Migraine prophylaxis: Moderate (small RCT plus meta-analysis; frequency/duration only).
• Mitochondrial disease / primary deficiency: standard-of-care by mechanism, rare-disease niche.
• Statin myopathy: Emerging-to-Moderate (conflicting RCTs, small and heterogeneous).

Practical takeaway

The framing to hold: CoQ10 is a targeted therapeutic for a few specific conditions, not a general tonic. If you are a healthy person taking it for energy or longevity, you are spending money on a poorly-absorbed supplement with no demonstrated benefit. Where it is warranted, take it with dietary fat.

Don't take it for the mass-market reasons.
• Energy / anti-aging in a healthy person: skip it. There is no demonstrated energy or longevity benefit in people who are not deficient; the endogenous supply already covers you.

The genuine niches (and how firm each is).
• Chronic heart failure: a real mortality signal exists (Q-SYMBIO, 100 mg three times daily), but it rests on a single manufacturer-funded trial and CoQ10 is an adjunct to, never a replacement for, guideline-directed heart-failure therapy. Any use here belongs in a conversation with the treating clinician — see cardiovascular_health_management.
• Migraine prevention: modest, real benefit at roughly 300 mg/day — fewer and shorter attacks, though not less severe. A reasonable low-risk prophylaxis adjunct.
• Primary CoQ10 deficiency / mitochondrial disease: obligatory replacement therapy, but managed by a specialist; response is variable. Not a self-directed use.
• Statin muscle pain: plausible and low-risk to try, but the trials genuinely conflict — frame it as "worth trialling, not proven," and do not stop a statin on the assumption CoQ10 will fix the symptoms.

If you do take it, take it right.
• Always with a fat-containing meal — oral absorption is only a few percent, and fat substantially improves it. An empty-stomach dose is mostly wasted.
• Don't overpay for ubiquinol reflexively. It is modestly better absorbed in some studies, but the body inter-converts the forms and formulation quality (oil-based, micronised softgels) matters more. Pay for a well-formulated product, not for the label.

Know the honest ceiling. Outside the specific niches above, the expected benefit is essentially nil, and even within them (heart failure aside) CoQ10 is a modest adjunct, not a primary treatment.

Evidence detail

Why This Entry Exists

CoQ10 sits at an awkward intersection: it is a genuinely useful molecule in a few specific conditions and a mass-market money-sink in everyone else, and the marketing deliberately blurs the two. The ATP-cofactor mechanism ("it powers your cells' energy factories") is real biochemistry, and it is then stretched into a claim it does not support — that a supplement raises functional energy and slows aging in ordinary healthy adults. It does not. So this entry has to do two opposite jobs at once: defend the real niches against a lazy "supplements don't work" dismissal, and dismantle the "everyone should take it for energy" pitch that the same word — CoQ10 — is used to sell.

The failure modes run in both directions. Over-claim it as a general tonic and a healthy person spends money on an unabsorbed supplement with no demonstrated benefit. Dismiss it entirely and you miss that it carries a hard mortality endpoint in one heart-failure trial, is standard replacement therapy in a rare mitochondrial-disease population, and modestly cuts migraine frequency. The consumer-facing "flagship" use — taking it to prevent statin muscle pain — is, ironically, the least evidence-proven of its plausible niches: the randomised trials genuinely conflict, and the honest line there is "plausible, low-risk to try, but not proven," not "clinically shown to work." Getting that ordering right — strong debunk of the mass-market claim, honest hedging on statins, and a small set of defended real niches — is the whole point of the entry.

What bad advice this protects against, in all directions:
• "CoQ10 boosts your energy — everyone should take it" → in healthy, non-deficient people there is no demonstrated energy benefit; endogenous synthesis plus diet already prevents deficiency, and the ATP-cofactor mechanism does not translate to a functional effect.
• "It slows aging / extends lifespan" → there is limited human evidence it prolongs life or prevents age-related functional decline; the "anti-aging" framing is a marketing construct, not a trial finding.
• "CoQ10 fixes statin muscle pain — it's proven" → the RCTs are genuinely equivocal: some meta-analyses find benefit, others (including analyses of myalgia and adherence) find none; it is plausible and low-risk to try, not proven.
• "CoQ10 treats heart failure" → one manufacturer-funded trial (Q-SYMBIO) showed a real mortality signal, but it is adjunctive to — never a replacement for — guideline-directed heart-failure therapy, and it rests on a single unreplicated trial (see cardiovascular_health_management).
• "Ubiquinol is far superior — always pay for it" → it is modestly better absorbed in some studies, but the body inter-converts the two forms and formulation quality matters more than the ubiquinone-versus-ubiquinol label; the ubiquinol premium is often not worth it.
• "Take it any way, any time" → oral CoQ10 is only a few percent absorbed and needs dietary fat; taking it on an empty stomach wastes most of the dose.
• "It doesn't work, skip it" → the reverse over-correction; it has real, narrow niches (heart-failure signal, mitochondrial disease, modest migraine) that a blanket dismissal misses.

This entry owns the CoQ10 niche-versus-mass-market verdict and the absorption/form reality. It defers the general label-literacy and elemental-dose principle to supplement_form_elemental_dose_and_bioavailability, and actual cardiovascular management (including where CoQ10 sits relative to guideline-directed heart-failure therapy) to cardiovascular_health_management. It states those boundaries and routes there rather than re-arguing them.

Evidence

Organised by use case, with the tier signal inline. The debunk of the mass-market claim and the absorption reality are the firmest parts; the niches split sharply in confidence — read the tiers, not just the thesis.

The mass-market claim fails: no energy or anti-aging benefit in healthy people (Strong debunk).

1. In healthy, non-deficient adults, CoQ10 shows no demonstrated energy or longevity benefit. Endogenous synthesis plus dietary intake provides enough CoQ10 to prevent deficiency in healthy adults, and there is limited evidence that supplementation prolongs life or prevents age-related functional decline in humans; across non-deficient conditions the overall RCT picture is described as contrasting and inconclusive. The ATP-cofactor mechanism is real, but it does not translate into a functional benefit in people who are not deficient — which is precisely the population the mass-market pitch targets. (Linus Pauling Institute, Oregon State University, Micronutrient Information Center: Coenzyme Q10; consistent with Hernández-Camacho JD, et al. "Coenzyme Q10 Supplementation in Aging and Disease." Front Physiol 2018, PMC5807419. Strong Evidence for the debunk — the absence of benefit in healthy adults directly refutes the "boosts energy / slows aging" claim; independent academic/university sources, no seller interest.)

The heart-failure niche: a real mortality signal, but one manufacturer-funded trial (Solid but single).

2. Q-SYMBIO showed a mortality signal in chronic heart failure — the single strongest result for CoQ10. In 420 patients with chronic heart failure randomised to CoQ10 100 mg three times daily added to standard therapy versus placebo for two years, major adverse cardiovascular events were cut roughly in half (HR 0.50, 95% CI 0.32–0.80), and two-year all-cause mortality was about 10% on CoQ10 versus 18% on placebo. This is the anchor of the heart-failure niche and the best hard-endpoint evidence CoQ10 has. (Mortensen SA, et al. "The Effect of Coenzyme Q10 on Morbidity and Mortality in Chronic Heart Failure: Results From Q-SYMBIO." JACC: Heart Failure 2014, PMID 25282031. Moderate — one adequately-powered double-blind RCT with a hard mortality endpoint is solid but not confirmed: a single trial, never independently replicated at this scale, enrolment spanning roughly a decade. Supports Moderate, not Strong. Partly funded by Pharma Nord ApS — maker of the Bio-Quinone ubiquinone tested — and Kaneka Corp plus the International Coenzyme Q10 Association; the sponsor manufactured the product, a structural conflict of interest, and cui bono clearly favours a positive result. Adjunctive to, never a replacement for, guideline-directed therapy — see cardiovascular_health_management.)

The statin-myopathy niche: the flagship consumer use, and the least proven (Genuinely equivocal).

3. For statin-associated muscle symptoms the RCT evidence is conflicting, not settled either way. Some meta-analyses report that CoQ10 reduces statin-related muscle pain and weakness; others — including analyses focused on myalgia and statin adherence — find no significant benefit over placebo. The trials are small and heterogeneous (typically tens to low-hundreds of patients on 100–600 mg/day for a few weeks to a few months), so the honest read is "unresolved." This is the everyday consumer use for CoQ10, and it is the least evidence-proven of its plausible niches. (Positive: Qu H, et al. "Effects of Coenzyme Q10 on Statin-Induced Myopathy: An Updated Meta-Analysis of Randomized Controlled Trials." J Am Heart Assoc 2018, PMID 30371340. Null: systematic review/meta-analysis on statin-associated myalgia and adherence, Atherosclerosis 2020, S0021-9150(20)30138-6. Emerging-to-Moderate at best — conflicting RCTs, small samples, high heterogeneity. The supplement industry, e.g. Life Extension, promotes this use by citing the positive meta-analyses while omitting the null ones — selective citation is the cui-bono tell here.)

The migraine niche: modest and real, but partial (Moderate).

4. CoQ10 gives modest migraine prophylaxis — fewer and shorter attacks, but not less severe. At roughly 300 mg/day, CoQ10 reduces monthly migraine attack frequency and attack duration, with reported quality-of-life gains, but meta-analysis shows no statistically significant reduction in attack severity. The effect is real but partial — a frequency/duration benefit, not a severity fix. (Sándor PS, et al. "Efficacy of coenzyme Q10 in migraine prophylaxis: A randomized controlled trial." Neurology 2005; corroborated by meta-analysis in J Headache Pain, PMC7786797. Moderate — a small positive RCT plus a supportive meta-analysis, with the effect confined to frequency and duration. Migraine is a legitimate, guideline-recognised low-risk prophylaxis niche and the commercial incentive here is lower than the mass-market energy pitch.)

The mitochondrial-disease niche: obligatory replacement, but often disappointing (Rare-disease standard-of-care).

5. In primary CoQ10 deficiency and mitochondrial disease, CoQ10 is standard replacement therapy — but response is variable and often modest. Because these patients lack the molecule, supplementation is the mechanistically obligatory treatment; but a systematic review found only about 27% (24 of 89 evaluable cases, from 303 identified) of primary-CoQ10-deficiency patients reported improvement, limited by poor tissue distribution, especially to the central nervous system. This is a genuine but rare therapeutic niche, distinct from anything the mass market implies. (Systematic review: "The efficacy of coenzyme Q10 treatment in alleviating the symptoms of primary coenzyme Q10 deficiency," 2022, PMC9443948; Hargreaves IP. "Coenzyme Q10 as a therapy for mitochondrial disease." Int J Biochem Cell Biol 2014, PMID 24495877. Standard-of-care by mechanism — replacing a deficient molecule — rather than by large RCTs; a rare-disease niche, not evidence for general use. No meaningful commercial-bias concern; the risk here runs the other way, using rare-disease legitimacy to imply general benefit.)

The absorption reality: poorly absorbed, take with fat, form matters less than formulation (Strong pharmacokinetics).

6. Oral CoQ10 is poorly absorbed — roughly 2–3% — and needs dietary fat; the ubiquinol premium is often not worth it. CoQ10 is a large, highly lipophilic molecule with very low aqueous solubility, so oral bioavailability is only a few percent and improves substantially when taken with a fat-containing meal. Ubiquinol is modestly better absorbed than ubiquinone in some crossover studies (notably in older men), but formulation quality — oil-based, micronised softgels — matters more than the ubiquinone-versus-ubiquinol choice, and blood CoQ10 exists almost entirely as ubiquinol regardless of which form is ingested, because the body inter-converts them. (Mantle D, Dybring A. "Bioavailability of Coenzyme Q10: An Overview of the Absorption Process and Subsequent Metabolism." Antioxidants 2020, PMC7278738; StatPearls, "Coenzyme Q10," NBK531491. Strong — well-established pharmacokinetics; the practical rule — take with fat, formulation beats form, the ubiquinol premium is frequently not worth it — is high-confidence. The ubiquinol upsell is a classic "superior absorption" price-justifier; Kaneka, the ubiquinol patent holder, is the beneficiary.)

Mechanism

This entry owns the use-case hierarchy and the absorption reality, not the full label-literacy/dosing principle, which is deferred to supplement_form_elemental_dose_and_bioavailability. What follows is only enough mechanism to make the niches and the ceiling intelligible.

Why the "energy" claim is biochemically real but functionally empty in healthy people. CoQ10 is an obligate electron carrier in the mitochondrial electron-transport chain, so it genuinely is a cofactor in ATP production — that is the sliver of truth the marketing rests on. But healthy adults synthesise CoQ10 endogenously and get more from diet, so they are not short of it; adding more does not push a saturated system to make more usable energy or slow aging. "Cofactor in energy production" is not the same as "raises your energy," and the gap between those two statements is where the mass-market pitch lives.

Why the niches are real: deficiency, not abundance, is the lever. CoQ10 helps precisely where the system is short of it or under stress. In primary CoQ10 deficiency the molecule is literally missing, so replacing it is obligatory (though poor tissue penetration, especially to the CNS, caps the benefit). In heart failure, failing cardiac muscle is energy-starved and oxidatively stressed, giving a plausible substrate for a supplemental effect — which is the mechanistic story behind the Q-SYMBIO signal. In migraine, mitochondrial energy metabolism in the brain is implicated in attack generation, so a mitochondrial cofactor plausibly reduces attack frequency. The common thread: benefit tracks a deficit or a stressed, energy-hungry tissue, not a healthy well-fed one.

Why statin myopathy is the plausible-but-unproven case. Statins inhibit HMG-CoA reductase, which sits upstream of both cholesterol and CoQ10 synthesis, so statins can lower circulating CoQ10 — the mechanistic rationale for repletion. That rationale is clean, which is why the use is plausible. But a plausible mechanism is not a demonstrated clinical effect, and the RCTs testing whether repletion actually reduces statin muscle symptoms genuinely disagree. Mechanism explains why people try it; it does not settle whether it works.

Why absorption caps the whole thing. CoQ10 is large and highly lipophilic with almost no water solubility, so the gut absorbs only a few percent, and that fraction rises with dietary fat. The ubiquinone-versus-ubiquinol distinction matters less than sellers imply because the body inter-converts the forms and formulation dominates the real-world difference. This is why "take it with fat" is the single highest-yield practical instruction, and why an empty-stomach dose is largely wasted.

Risks And Contraindications

• The main risk is opportunity cost and false reassurance, not toxicity. CoQ10 is generally very well tolerated. The realistic harm in healthy people is money spent on an unabsorbed, non-beneficial supplement, plus the false confidence that they are "doing something" for energy or aging when they are not.
• Warfarin interaction — real and clinically meaningful. CoQ10 is structurally similar to vitamin K and may blunt warfarin's anticoagulant effect (reducing the INR). Anyone on warfarin should not add CoQ10 without clinician oversight and INR monitoring.
• Do not overstate the heart-failure case. It rests on a single manufacturer-funded trial and has not been independently replicated at scale. CoQ10 is adjunctive to, never a substitute for, guideline-directed heart-failure therapy — defer actual cardiovascular management to cardiovascular_health_management. Never let a supplement displace a prescribed heart-failure medication.
• Do not imply statin-myopathy benefit is proven. The RCTs conflict; the honest line is "plausible, low-risk to try, but not demonstrated." Critically, CoQ10 is not a reason to stop or skip a prescribed statin — a patient stopping a cardioprotective drug because they believe a supplement handles the side effect is the dangerous over-claim to avoid.
• Keep the niches at their real confidence, and don't generalise them. The heart-failure signal, the migraine benefit, the mitochondrial-disease replacement, and the statin question are separate cases at different evidence levels; a benefit in one does not license the mass-market "everyone should take it" claim.
• Avoid the opposite over-correction. "CoQ10 does nothing" is also wrong: it has real, narrow niches. The honest message is "narrow but real, not a general tonic," not a blanket dismissal.

Controversy

Nature: a supplement with a handful of genuinely evidenced niches wrapped in a mass-market "energy and anti-aging tonic" pitch that the evidence does not support, with error possible at both poles — over-claiming CoQ10 as a general benefit on one side, and dismissing it as useless on the other.

Position A — "CoQ10 has real, evidenced uses." The defended-niches take.
• Best evidence: a mortality signal in chronic heart failure (Q-SYMBIO, hard endpoint); obligatory replacement in primary CoQ10 deficiency and mitochondrial disease; modest migraine prophylaxis (fewer, shorter attacks); and a mechanistically plausible — if unproven — role in statin muscle pain. Each is real within its stated bounds.
• Where it goes wrong if overstated: it slides into "everyone should take CoQ10," treats the single heart-failure trial as settled, or presents the statin use as proven.

Position B — "The mass-market pitch is unsupported." The debunk take.
• Best evidence: healthy people synthesise enough endogenously; there is no demonstrated energy or longevity benefit in non-deficient adults; oral absorption is only a few percent without fat; and even the flagship statin-myopathy use has conflicting RCTs. The "cellular energy / anti-aging" framing is a marketing construct.
• Where it goes wrong if overstated: it can tip into "CoQ10 is useless," which ignores the real heart-failure signal, the rare-disease replacement role, and the modest migraine benefit.

The funding/bias dimension — cui bono, both ways. Toward over-claiming: the pro-CoQ10 side carries most of the commercial pressure. The flagship heart-failure trial was co-funded by the ubiquinone manufacturer (Pharma Nord) and the ubiquinol patent holder (Kaneka) plus the industry-aligned International Coenzyme Q10 Association; consumer promoters cite the positive statin meta-analyses while omitting the null ones; and the ubiquinol "superior absorption" upsell justifies a higher price the body's own inter-conversion largely erases. Toward the corrective pole: cui bono the other way is weak — CoQ10 is off-patent and cheap to make, so there is little organised interest in suppressing it; the healthy-adult null and the poor-absorption findings serve no seller and come from independent academic sources.

Realised Position: Real but narrow. CoQ10 is a targeted therapeutic for specific cardiac, metabolic and neurological indications, not a general tonic. For a healthy person chasing energy or longevity it is money spent on a supplement with no demonstrated benefit and poor absorption. Its genuine niches are the heart-failure mortality signal (from a single manufacturer-funded trial, adjunct only), obligatory replacement in mitochondrial disease, and modest migraine prevention; its flagship consumer use (statin muscle pain) is plausible and low-risk to try but not proven. Where CoQ10 is warranted, it must be taken with dietary fat, and the ubiquinol premium is usually not worth paying.

Cross-Pillar Connections

CoQ10 is a diet/supplement topic with a genuine cardiac tail, so its connections span the supplement-literacy and cardiovascular lines.
• Conditions (cardiovascular_health_management): owns actual cardiovascular management, including where CoQ10 sits relative to guideline-directed heart-failure therapy; this entry holds only that a mortality signal exists in one trial and that CoQ10 is adjunct-only, and defers management there.
• Supplements (supplement_form_elemental_dose_and_bioavailability): owns the general label-literacy, elemental-dose and bioavailability principle; this entry holds only the CoQ10-specific absorption reality (few-percent absorption, take with fat, formulation over form) and defers the general framework there.
• Supplements (universal_nearuniversal_supplementation): the reference point for which supplements clear the bar for near-universal use — CoQ10 conspicuously does not, which is the contrast this entry draws.
• Foundations (publication_bias_and_evidence_distortion): the mechanism behind the selective-citation and single-sponsored-trial pattern that inflates CoQ10's apparent evidence.
• Foundations (healthy_user_bias): why observational "CoQ10 users are healthier" impressions do not establish a supplement benefit — relevant to reading the mass-market claims critically.

What would change our mind

Industry bias note

Sources (9)

• Linus Pauling Institute, Oregon State University, Micronutrient Information Center. "Coenzyme Q10." (Independent/academic; no seller interest.) — endogenous synthesis plus diet prevents deficiency in healthy adults; limited evidence for life-prolongation or prevention of age-related decline; overall RCT picture across non-deficient conditions contrasting/inconclusive.↗
• Hernández-Camacho JD, et al. (2018). "Coenzyme Q10 Supplementation in Aging and Disease." Front Physiol, PMC5807419. (Independent/academic review.) — corroborates the limited functional benefit in non-deficient/aging populations.↗
• Mortensen SA, et al. (2014). "The Effect of Coenzyme Q10 on Morbidity and Mortality in Chronic Heart Failure: Results From Q-SYMBIO." JACC: Heart Failure, pubmed.ncbi.nlm.nih.gov/25282031↗/" target="_blank" rel="noopener">PMID 25282031↗. (Sponsor-conflicted — co-funded by Pharma Nord (maker of the tested ubiquinone), Kaneka, and the International Coenzyme Q10 Association; single, unreplicated trial.) — n=420 chronic HF, CoQ10 100 mg three times daily, 2 yr: MACE HR 0.50 (95% CI 0.32–0.80); 2-yr all-cause mortality ~10% vs ~18% placebo.
• Qu H, et al. (2018). "Effects of Coenzyme Q10 on Statin-Induced Myopathy: An Updated Meta-Analysis of Randomized Controlled Trials." J Am Heart Assoc, pubmed.ncbi.nlm.nih.gov/30371340↗/" target="_blank" rel="noopener">PMID 30371340↗. (Positive meta-analysis; supplement sellers cite this one.) — reports reduced statin muscle pain/weakness.
• Systematic review/meta-analysis on statin-associated myalgia and adherence (2020). Atherosclerosis, S0021-9150(20)30138-6. (Null result; the one sellers tend to omit.) — no significant CoQ10 benefit over placebo for statin-associated myalgia/adherence.↗
• Sándor PS, et al. (2005). "Efficacy of coenzyme Q10 in migraine prophylaxis: A randomized controlled trial." Neurology; corroborated by meta-analysis in J Headache Pain, PMC7786797. (Academic; lower commercial incentive than the energy pitch.) — ~300 mg/day reduced attack frequency and duration; meta-analysis found no significant reduction in severity.↗
• Systematic review (2022). "The efficacy of coenzyme Q10 treatment in alleviating the symptoms of primary coenzyme Q10 deficiency." PMC9443948; with Hargreaves IP. (2014). "Coenzyme Q10 as a therapy for mitochondrial disease." Int J Biochem Cell Biol, pubmed.ncbi.nlm.nih.gov/24495877↗/" target="_blank" rel="noopener">PMID 24495877↗. (Academic; rare-disease population, no meaningful commercial-bias concern.) — only ~27% (24 of 89 evaluable cases, from 303 identified) of primary-CoQ10-deficiency patients reported improvement; response limited by poor tissue/CNS distribution.
• Mantle D, Dybring A. (2020). "Bioavailability of Coenzyme Q10: An Overview of the Absorption Process and Subsequent Metabolism." Antioxidants, PMC7278738; with StatPearls, "Coenzyme Q10," NBK531491. (Academic pharmacokinetics; the ubiquinol premium benefits patent-holder Kaneka.) — oral bioavailability ~2–3%; improved by dietary fat; ubiquinol modestly better absorbed in some crossover studies but formulation dominates and forms inter-convert in the body.↗
• Funding notation: the load-bearing counter-claims (no benefit in healthy adults; poor absorption) come from independent academic sources with no seller interest, and CoQ10's off-patent, cheap-to-make status means there is no organised interest in suppressing it — so those claims are trustworthy. The most commercially-motivated claims (the heart-failure mortality signal from a manufacturer-funded single trial, the selectively-cited positive statin meta-analyses, and the ubiquinol "superior absorption" upsell) are exactly the ones the entry marks and hedges. The bias vector runs almost entirely toward over-claiming benefit.*↗

Related entries